Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Down 10% – Time to Sell?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)’s share price dropped 10% during trading on Thursday . The company traded as low as $18.50 and last traded at $19.04. Approximately 241,599 shares traded hands during trading, an increase of 10% from the average daily volume of 218,704 shares. The stock had previously closed at $21.15.

Analyst Upgrades and Downgrades

DMRA has been the topic of several research reports. Lifesci Capital raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, February 2nd. Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. UBS Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They set a “buy” rating and a $45.00 target price for the company. Wall Street Zen raised shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Leerink Partners assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They set an “outperform” rating and a $46.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.67.

Damora Therapeutics, Inc. Common Stock Stock Performance

The stock has a 50-day moving average price of $26.93 and a two-hundred day moving average price of $18.90. The stock has a market capitalization of $1.05 billion, a PE ratio of -1.50 and a beta of 1.42.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds have recently modified their holdings of DMRA. Janus Henderson Group PLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $40,000. Geode Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $266,000. Virtu Financial LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $49,000. Sigma Planning Corp purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $334,000. Finally, Two Sigma Investments LP purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $76,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.